|
|
Post by fldave007 on Apr 17, 2019 7:42:34 GMT -5
A lot of things have been tried to get sales moving in the right direction with little success. Maybe Mnkd should concentrate on completing the trials for pediatrics and then once approved start advertising like crazy geared towards parents and younger people. Unfortunately older people are much slower to embrace change younger people are not. I think that is where our focus should be for now.
|
|
|
|
Post by traderdennis on Apr 17, 2019 7:51:17 GMT -5
A lot of things have been tried to get sales moving in the right direction with little success. Maybe Mnkd should concentrate on completing the trials for pediatrics and then once approved start advertising like crazy geared towards parents and younger people. Unfortunately older people are much slower to embrace change younger people are not. I think that is where our focus should be for now. If it was a older versus younger issue then why have millennial t1s not embraced Afrezza. Certainly there are enough of this cohort to have more than a few hundreds weekly scripts. |
|
|
|
Post by winstonsmith on Apr 17, 2019 7:52:13 GMT -5
In my opinion the reason the TV ads didn't work is because the commercial is horrible and doesn't separate it from the pack.....which is getting rid of needles and working fast and ease of use. Until they make that very obvious for brain dead America, it's not going anywhere on TV. They need a new TV ad and can also do something very similar on social media and radio.
|
|
|
|
Post by mannmade on Apr 17, 2019 9:42:56 GMT -5
Find a millenial You Tube star who is diabetic and get him or her to promote on social media. Like Sam Pottoroff
|
|
|
|
Post by seanismorris on Apr 17, 2019 10:43:13 GMT -5
In my opinion the reason the TV ads didn't work is because the commercial is horrible and doesn't separate it from the pack.....which is getting rid of needles and working fast and ease of use. Until they make that very obvious for brain dead America, it's not going anywhere on TV. They need a new TV ad and can also do something very similar on social media and radio. Mixed feelings on this one... The consensus (on proboards) NOW is the commercial is horrible, which is where I’ve been all along... when I was the hater minority. I’m wondering if the consensus next is going to agree: - international efforts to sell Afrezza are PR - VDEX is irrelevant in moving the needle - If the Pediatric study data doesn’t blow us away, Afrezza will remain irrelevant - not blitzing the internet with Afrezza ads was criminally stupid - Mike has moved on from Afrezza besides the “dog and pony show” for investors - Technosphere is MannKinds future - longs are never getting our investment back Looking at MNKD’s stock... too many people are coming to agree (on Afrezza). I’d like to think Technosphere still has considerable value, but maybe the pipeline is to much in the early stage to generate excitement... I still have a small hope Afrezza will become more than a niche product but that’s in the pediatric space and a relatively small market. Do we need a “large” sales team for that? I think the “next move” is some honesty from MannKind’s management This repeated dillusion without adequate warning isn’t helping the stock price or suggesting competence or ability to make MannKind a profitable company. If Technosphere is MannKind’s future we need more insight into this “embarrassment of riches”. We need some buzz in the worst way. What are potential partners interested in... Please say pain. |
|
|
|
Post by winstonsmith on Apr 17, 2019 21:02:10 GMT -5
.......or simply get an effective marketing campaign to pull patients into use. Afrezza is the real deal but Mannkind hasn't a clue on how to do an awesome marketing campaign. Maybe MC isn't the right guy if he can't get that going. So far he's just wasting money on ads that don't get noticed.
|
|
|
|
Post by lifebreath on Apr 17, 2019 22:12:35 GMT -5
.......or simply get an effective marketing campaign to pull patients into use. Afrezza is the real deal but Mannkind hasn't a clue on how to do an awesome marketing campaign. Maybe MC isn't the right guy if he can't get that going. So far he's just wasting money on ads that don't get noticed. It is literally shocking to me how poorly done the marketing campaign and relaunch is. My question at the ASM would be directed to Kent Kresa. I would ask; Do to the failed launch and marketing campaign orchestrated by CEO Castagna at what point will you begin looking for a new CEO or are you already? |
|
|
|
Post by ltta on Apr 17, 2019 22:14:26 GMT -5
.......or simply get an effective marketing campaign to pull patients into use. Afrezza is the real deal but Mannkind hasn't a clue on how to do an awesome marketing campaign. Maybe MC isn't the right guy if he can't get that going. So far he's just wasting money on ads that don't get noticed.
1000% agree.... what gives??? Marketing gets an F- in pay scale.
|
|
|
|
Post by cedafuntennis on Apr 17, 2019 23:48:45 GMT -5
.......or simply get an effective marketing campaign to pull patients into use. Afrezza is the real deal but Mannkind hasn't a clue on how to do an awesome marketing campaign. Maybe MC isn't the right guy if he can't get that going. So far he's just wasting money on ads that don't get noticed. It is literally shocking to me how poorly done the marketing campaign is. My question at the ASM would be directed to Kent Kresa. I would ask; Do to the failed launch and marketing campaign orchestrated by CEO Castagna at what point will you begin looking for a new CEO or are you already? It is NOT the CEO's job to design and run marketing campaigns. They hired someone only for that purpose and they are doing a MISERABLE job. Same for the PR agency they waste money on. Those entities MUST go now and get someone who has a clue. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 18, 2019 7:17:14 GMT -5
It is literally shocking to me how poorly done the marketing campaign is. My question at the ASM would be directed to Kent Kresa. I would ask; Do to the failed launch and marketing campaign orchestrated by CEO Castagna at what point will you begin looking for a new CEO or are you already? It is NOT the CEO's job to design and run marketing campaigns. They hired someone only for that purpose and they are doing a MISERABLE job. Same for the PR agency they waste money on. Those entities MUST go now and get someone who has a clue. You guys crack me up. You expect a company to CREATE a sales organization and be #1 in SALES after 2 years? Hell it took the NY Mets 7 years to win a WORLD SERIES in 1969 and that was a fluke. It's going to take time. Mike has said insurance companies usually get onboard with full coverage after 3 years of a drug being on the market. Now it might be a little faster if you're a Merck, Pfizer or even Novo but for a company with their 1st drug??? It's going to take time. Mike showed a chart of when new drugs start and the hockey stick forms in Year 3. And for the naysayers who say Afrezza has been on the market for 4 years now - that is disqualified due to Sanofi. The clock restarted when MNKD decided to create a Sales Org and go it alone. So we are in Year 2 of the RELAUNCH. It's going to take time. |
|
|
|
Post by hellodolly on Apr 18, 2019 7:26:07 GMT -5
A lot of things have been tried to get sales moving in the right direction with little success. Maybe Mnkd should concentrate on completing the trials for pediatrics and then once approved start advertising like crazy geared towards parents and younger people. Unfortunately older people are much slower to embrace change younger people are not. I think that is where our focus should be for now. . Certainly there are enough of this cohort to have more than a few hundreds weekly scripts. We do not know who has and hasn't embraced Afrezza? There are no break outs of that demographic data, so it's very presumptuous on your part to make that kind of statement. You can't go to FB, Instagram, Twitter or Snapchat and tell us you have any empirical data points to back up your statement and those are all millennial tools. How many people n Snapchat, FB, Instagram and Twitter are PWD's? This board has debated at length the potential causes for the slow Rx growth, with insurance, marketing and uninformed doctors as the lead talking points. |
|
|
|
Post by matt on Apr 18, 2019 7:57:39 GMT -5
This board has debated at length the potential causes for the slow Rx growth, with insurance, marketing and uninformed doctors as the lead talking points. Afrezza may simply rest in what is described in the business literature as "The No Profit Zone"; there are lots of examples across all industries. Afrezza has its charms, no doubt, but it comes at a very high price relative to other options and managed care companies do not seem inclined to pay up for the additional value-added features, and physicians do not seem to convinced enough in the incremental benefits of Afrezza to fight the battle either. Afrezza has a high manufacturing cost relative to competitors, and even at higher production volume the cost disparity will remain, and the competition has started to retreat on recent price increases in face of public and Congressional criticism. When entrenched competitors have an absolute cost advantage and are rolling back pricing to earlier levels, the opportunity to ever make money on Afrezza may well be unachievable. That leaves the pipeline. Any drug that comes out of the pipeline effort will have the same manufacturing cost disadvantage as Afrezza, but inhaled delivery is a bigger deal for some drugs than for others. If MNKD carefully targets indications where inhalation provides a significant therapeutic advantage, there might be a workable strategy to turn the company around. If MNKD pursues formulations for any generic medication without regard to the increase in therapeutic benefit, they will likely not be successful. TreT is a good example of a drug where the increase in therapeutic benefit may outweigh the additional cost of production, epinephrine is not. |
|
|
|
Post by Clement on Apr 18, 2019 8:06:37 GMT -5
Epi pens are inexpensive?
|
|
|
|
Post by letitride on Apr 18, 2019 8:10:11 GMT -5
Is there an ignore feature on proboard. I want to make that my next move.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 18, 2019 8:23:24 GMT -5
This board has debated at length the potential causes for the slow Rx growth, with insurance, marketing and uninformed doctors as the lead talking points. Afrezza may simply rest in what is described in the business literature as "The No Profit Zone"; there are lots of examples across all industries. Afrezza has its charms, no doubt, but it comes at a very high price relative to other options and managed care companies do not seem inclined to pay up for the additional value-added features, and physicians do not seem to convinced enough in the incremental benefits of Afrezza to fight the battle either. Afrezza has a high manufacturing cost relative to competitors, and even at higher production volume the cost disparity will remain, and the competition has started to retreat on recent price increases in face of public and Congressional criticism. When entrenched competitors have an absolute cost advantage and are rolling back pricing to earlier levels, the opportunity to ever make money on Afrezza may well be unachievable. That leaves the pipeline. Any drug that comes out of the pipeline effort will have the same manufacturing cost disadvantage as Afrezza, but inhaled delivery is a bigger deal for some drugs than for others. If MNKD carefully targets indications where inhalation provides a significant therapeutic advantage, there might be a workable strategy to turn the company around. If MNKD pursues formulations for any generic medication without regard to the increase in therapeutic benefit, they will likely not be successful. TreT is a good example of a drug where the increase in therapeutic benefit may outweigh the additional cost of production, epinephrine is not. And you know something Matt...The world is going to end in 2022. OMG you are such a glass half empty guy. Everything you expounded on about Afrezza are the characteristics of a NEW DRUG and NEW THERAPY being introduced. Once Doctors and Insurance Companies realize the benefits on being on Afrezza they will jump on board. It will take time to gain momentum. There is no reason to panic. If Afrezza had a better label from the beginning the roll out would have been a lot smoother. But that's not the case so no need to cry about it. With full coverage and maximum production Afrezza will command 70% profit margins. Now the question is will that come with an in-house Sales Org or a Partner? Either way there's a great potential for Afrezza. Wait until PEDS is approved and EU filing. The evidence is being formulated now that Technosphere is a viable platform for drugs that cannot deliver the needed benefit in their current state. TreT or Dryvaso is a clear example. If development continues and shows greater benefit the pharma industry will wake up to MNKD and their technology. Good things to come!! Hoping your glass is now HALF FULL...... |
|
